Restricts the use of certain products by governmental entities and government-funded entities. (BDR 19-737)
Summary
AB 208 restricts how certain governmental entities and government-funded entities may use, provide, or dispense “federally reviewed products” in covered facilities. The bill applies to facilities that provide care, treatment, or training for persons with mental illnesses, as well as correctional facilities such as prisons, community correctional centers, conservation camps, and other places of confinement. In general, a covered entity may not use a product in a way that conflicts with the patent holder’s terms of use, the product’s written directions or limitations, or the product’s approved federal uses.
The bill creates a notice-and-objection process. A covered entity may proceed with a nonconforming use only after giving written notice to the patent holder and manufacturer or distributor and waiting 30 days without objection. If an objection is received, the entity must stop the nonconforming use unless all objecting parties later withdraw their objections. The bill also allows a covered entity to provide or dispense a product for a nonconforming use if the resident gives informed consent, and in that case notice to the patent holder and manufacturer is not required. The measure expressly states it cannot be interpreted to require any action that would violate conditions attached to federal funding.
Impact
AB 208 would add a new section to Chapter 237 of the Nevada Revised Statutes and directly regulate state and local governmental entities, as well as certain government-funded entities, operating mental health and correctional facilities. It would create legal limits on the use of patented or federally reviewed products, establish notice and objection procedures for manufacturers and patent holders, and define key terms such as covered facility, covered entity, resident, and federally reviewed product. The bill also includes an express safeguard for federal funding compliance and would take effect July 1, 2025, after immediate effectiveness for preparatory administrative work.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears procedural and policy-driven rather than openly partisan. The measure is framed as a regulatory safeguard for product use in institutional settings, with built-in exceptions for informed consent and federal funding requirements. No opposition or support was documented in the supplied discussion materials, so there is no clear record of controversy in the available context.
Contention
The main points of potential contention are the bill’s broad restriction on nonconforming use of patented or federally reviewed products and the role it gives patent holders and manufacturers to object and force cessation of use. Critics could view this as limiting clinical discretion or institutional flexibility in mental health and correctional settings, while supporters may see it as protecting product integrity, safety, and compliance with approved uses. Another possible issue is the interaction with federal funding conditions and whether the bill could constrain practices at publicly funded facilities, though the bill attempts to avoid that conflict by expressly preserving federal compliance.